Policy / Alpha Vantage News Sentiment

Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor

Oncolytics Biotech Inc. (ONCY) announced the replacement of Ernst & Young LLP with Baker Tilly US, LLP as its independent registered public accounting firm for the 2026 fiscal year due to corporate restructuring. The company confirmed that there were no disagreements with EY, and EY's previous audit reports for 2024 and 2025 were clean except for an explanatory paragraph regarding Oncolytics Biotech's ability to continue as a going concern.